Can your own immune cells fight advanced cancer?

NCT ID NCT07743723

First seen Aug 04, 2026 · Last updated Aug 07, 2026 · Updated 3 times

Summary

This trial is testing an experimental therapy called IOV-5001, which uses a patient's own immune cells (tumor-infiltrating lymphocytes) to attack cancer. The study involves adults with advanced solid tumors, including non-small cell lung cancer, triple-negative breast cancer, colorectal cancer, and head and neck cancer, that have not responded to prior treatments. Participants receive two infusions of their personalized cell therapy in a hospital setting. The goal is to see if this approach is safe and can shrink tumors.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
IOV-5001, a personalized cell therapy made from a patient's own tumor-infiltrating lymphocytes (TILs)
What this could lead to
If successful, this could offer a new treatment option for people with advanced solid tumors that have not responded to other therapies, potentially leading to durable remissions.
What could go wrong
This is an early-stage trial, so the therapy may not work for everyone or may cause severe side effects. The treatment involves a complex process and requires hospitalization.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMORS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Study contacts

  • Contact

    Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.